Frailty and transplantation

Transplantation

Volumn 100, Issue 4, 2016, Pages 727-733

  Exterkate, Leonie ^a,b   Slegtenhorst, Bendix R ^a,c   Kelm, Matthias ^a   Seyda, Midas ^a,d   Schuitenmaker, Jeroen M ^a,b   Quante, Markus ^a,e   Uehara, Hirofumi ^a,f   Khal, Abdala El ^a   Tullius, Stefan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; INTERLEUKIN 6; TESTOSTERONE;

AGING; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DELAYED GRAFT FUNCTION; END STAGE RENAL DISEASE; FRAIL ELDERLY; FRAILTY; HOSPITAL READMISSION; HUMAN; IMMUNOSENESCENCE; KIDNEY TRANSPLANTATION; MORTALITY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSICAL DISABILITY; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UREMIA; ADVERSE EFFECTS; AGE; AGED; COGNITION; FEMALE; GERIATRIC ASSESSMENT; GRAFT RECIPIENT; HEALTH STATUS; IMMUNOLOGY; MALE; METABOLISM; POSTOPERATIVE COMPLICATIONS; PSYCHOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGING; COGNITION; FEMALE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMANS; IMMUNOSENESCENCE; KIDNEY TRANSPLANTATION; MALE; PATIENT READMISSION; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84951299128     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001003     Document Type: Review

References (95)

1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-M156.
2. Fried LP, Xue Q, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64A: 1049-1057.
3. Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm-issues and controversies. J Gerontol A Biol Sci Med Sci. 2007;62:731-737.
4. Rockwood K. What would make a definition of frailty successful? Age Ageing. 2005;34:432-434.
5. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Scientific World Journal. 2001;1:323-336.
6. Rockwood K, Stadnyk K, MacKnight C, et al. A brief clinical instrument to classify frailty in elderly people. Lancet. 1999;353:205-206.
7. Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61:262-266.
8. McAdams-DeMarco MA, Law A, King E, et al. Frailty and mortality in kidney transplant recipients. Am J Transplant. 2015;15:149-154.
9. Derck JE, Thelen AE, Cron DC, et al. Quality of life in liver transplant candidates: frailty is a better indicator than severity of liver disease. Transplantation. 2015;99:340-344.
10. Ponticelli C, Podesta MA, Graziani G. Renal transplantation in elderly patients. How to select the candidates to the waiting list? Transplant Rev (Orlando). 2014;28:188-192.
11. Campisi J. Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes. Exp Gerontol. 2003;38:5-11.
12. Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol. 2006;41:1234-1238.
13. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal. 2009;11: 59-98.
14. Fedarko NS. The biology of aging and frailty. Clin Geriatr Med. 2011;27: 27-37.
15. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidi-ties: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333-2341.
16. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92-105.
17. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270.
18. Leng S, Chaves P, Koenig K, et al. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50:1268-1271.
19. Leng SX, Xue QL, Huang Y, et al. Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women. Exp Gerontol. 2005;40:982-987.
20. Leng SX, Xue QL, Tian J, et al. Inflammation and frailty in older women. J Am Geriatr Soc. 2007;55:864-871.
21. Wang GC, Kao WH, Murakami P, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010;171:1144-1152.
22. Leng SX, Tian X, Matteini A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing. 2011;40:475-481.
23. Parker DC, Mielke MM, Yu Q, et al. Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry. 2013;28:149-154.
24. Lynch HE, Goldberg GL, Chidgey A, et al. Thymic involution and immune reconstitution. Trends Immunol. 2009;30:366-373.
25. Aspinall R, Andrew D. Thymic involution in aging. J Clin Immunol. 2000; 20:250-256.
26. Goronzy JJ, Weyand CM.Tcell development and receptor diversity during aging. Curr Opin Immunol. 2005;17:468-475.
27. Yager EJ, Ahmed M, Lanzer K, et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med. 2008;205:711-723.
28. Semba RD, Margolick JB, Leng S, et al. Tcell subsets and mortality in older community-dwelling women. Exp Gerontol. 2005;40:81-87.
29. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol. 2004;36:35-38.
30. De Fanis U, Wang GC, Fedarko NS, et al. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc. 2008;56:904-908.
31. Wang GC, Casolaro V. Immunologic changes in frail older adults. Transl Med UniSa. 2014;9:1-6.
32. Gabriel H, Schmitt B, Kindermann W. Age-related increase of CD45RO+ lymphocytes in physically active adults. Eur J Immunol. 1993;23: 2704-2706.
33. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
34. Pieper CF, Rao KM, Currie MS, et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci. 2000;55:M649-M657.
35. Visser M, Deeg DJH, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab. 2003;88:5766-5772.
36. Puts MTE, Visser M, Twisk JWR, et al. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf). 2005;63: 403-411.
37. Leng SX, Cappola AR, Andersen RE, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16:153-157.
38. Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107: 123-136.
39. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci. 2002;57:M76-M99.
40. Kissick HT, Sanda MG, Dunn LK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci USA. 2014;111: 9887-9892.
41. Wu I, Lin X, Liu P, et al. Low serum testosterone and frailty in older men and women. Maturitas. 2010;67:348-352.
42. Travison TG, Nguyen A, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab. 2011;96:2464-2474.
43. Boirie Y, Gachon P, Cordat N, et al. Differential insulin sensitivities of glucose, amino acid, and albumin metabolism in elderly men and women. J Clin Endocrinol Metab. 2001;86:638-644.
44. Volpi E, Mittendorfer B, Rasmussen BB, et al. The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly. J Clin Endocrinol Metab. 2000;85:4481-4490.
45. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002;57:M326-M332.
46. Gill TM, Williams CS, Richardson ED, et al. Impairments in physical performance and cognitive status as predisposing factors for functional dependence among nondisabled older persons. J Gerontol A Biol Sci Med Sci. 1996;51:M283-M288.
47. Buchman AS, Boyle PA, Wilson RS, et al. Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. Psychosom Med. 2007;69:483-489.
48. Boyle PA, Buchman AS, Wilson RS, et al. Physical frailty isassociated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc. 2010;58:248-255.
49. Ávila-Funes JA, Amieva H, Barberger-Gateau P, et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc. 2009; 57:453-461.
50. Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preop-erative assessment using frailty, disability and co-morbidity. Ann Surg. 2009;250:449-455.
51. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment-a review of the evidence and causal mechanisms. Ageing Res Rev. 2013; 12:840-851.
52. Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2008;52: 227-234.
53. Feng L, Yap KB, Yeoh LY, et al. Kidney function and cognitive and functional decline in elderly adults: findings from the Singapore Longitudinal Aging Study. J Am Geriatr Soc. 2012;60:1208-1214.
54. Helmer C, Stengel B, Metzger M, et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C study. Neurology. 2011;77: 2043-2051.
55. Tamura MK, Muntner P, Wadley V, et al. Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. Am J Kidney Dis. 2011;58:756-763.
56. Buchman AS, Tanne D, Boyle PA, et al. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology. 2009;73: 920-927.
57. Davis DHJ, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain. 2012;135:2809-2816.
58. Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in he-modialysis patients is common. Neurology. 2006;67:216-223.
59. Kurella M, Chertow GM, Luan J, et al. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc. 2004;52:1863-1869.
60. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15: 123-132.
61. Griva K, Thompson D, Jayasena D, et al. Cognitive functioning pre-to post-kidney transplantation-a prospective study. Nephrol Dial Transplant. 2006;21:3275-3282.
62. Kramer L, Madl C, Stockenhuber F, et al. Beneficial effect of renal transplantation on cognitive brain function. Kidney Int. 1996;49:833-838.
63. Harciarek M, Biedunkiewicz B, Lichodziejewska-Niemierko M, et al. Continuous cognitive improvement 1 year following successful kidney transplant. Kidney Int. 2011;79:1353-1360.
64. Nevins TE, Robiner WN, Thomas W. Predictive patterns of early medication adherence in renal transplantation. Transplantation. 2014;98: 878-84.
65. Bethesda M. United States renal data system, 2014 annual data report: an overview of the epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014.
66. Rolland Y, Abellan van Kan G, Bénétos A, et al. Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives. J Nutr Health Aging. 2008;12:335-346.
67. Afilalo J. Frailty in patients with cardiovascular disease: why, when, and how to measure. Curr Cardiovasc Risk Rep. 2011;5:467-472.
68. Shlipak MG, Stehman-Breen C, Fried LF, et al. The presence offrailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004;43: 861-867.
69. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9Suppl 3:S1-S155.
70. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.
71. Jassal SV, Krahn MD, Naglie G, et al. Kidney transplantation in the elderly: a decision analysis. J Am Soc Nephrol. 2003;14:187-196.
72. Faravardeh A, Eickhoff M, Jackson S, et al. Predictors of graft failure and death in elderly kidney transplant recipients. Transplantation. 2013;96: 1089-1096.
73. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210:901-908.
74. Ommundsen N, Wyller TB, Nesbakken A, et al. Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 2014;19:1268-1275.
75. Robinson TN, Wu DS, Pointer L, et al. Simple frailty score predicts postoperative complications across surgical specialties. Am J Surg. 2013;206: 544-550.
76. Revenig LM, Canter DJ, Taylor MD, et al. Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoper-ative variables predictive of poor Surgical Outcomes. J Am Coll Surg. 2013;217:665-670.e1.
77. Lauzurica R, Pastor MC, Bayes B, et al. Pretransplant inflammation: a risk factor for delayed graft function? J Nephrol. 2008;21:221-228.
78. Garonzik-Wang JM, Govindan P, Grinnan JW, et al. Frailty and delayed graft function in kidney transplant recipients. Arch Surg. 2012;147:190-193.
79. McAdams-DeMarco M, Law A, Salter ML, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemo-dialysis. J Am Geriatr Soc. 2013;61:896-901.
80. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271-278.
81. Robinson TN, Wu DS, Stiegmann GV, et al. Frailty predicts increased hospital and six-month healthcare cost following colorectal surgery in older adults. Am J Surg. 2011;202:511-514.
82. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009;360: 1418-1428.
83. McAdams-DeMarco MA, Grams ME, Hall EC, et al. Early hospital read-mission after kidney transplantation: patient and center-level associations. Am J Transplant. 2012;12:3283-3288.
84. McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty and early hospital readmission after kidney transplantation. Am J Transplant. 2013;13: 2091-2095.
85. Schoonover H, Corbett CF, Weeks DL, et al. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medication regimen complexity. J Patient Saf. 2014;10:186-191.
86. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629-1634.
87. Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19:419-424.
88. Davies EA, O'Mahony MS. Adverse drug reactions in special populations-the elderly. Br J Clin Pharmacol. 2015;80:796-807.
89. Hubbard RE, O'Mahony MS, Calver BL, et al. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64:895-900.
90. Liu CK, Fielding RA. Exercise as an intervention for frailty. Clin Geriatr Med. 2011;27:101-110.
91. Waters DL, Baumgartner RN, Garry PJ, et al. Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging. 2010;5: 259-270.
92. Strollo F, Strollo G, Morè M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male. 2013;16:33-37.
93. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
94. Theou O, Stathokostas L, Roland KP, et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. J Aging Res. 2011;2011:569194.
95. Gill TM, Baker DI, Gottschalk M, et al. A prehabilitation program for physically frail community-living older persons. Arch Phys Med Rehabil. 2003; 84:394-404.